Wall Street analysts expect that Vistagen Therapeutics Inc (NASDAQ:VTGN) will report ($0.30) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Vistagen Therapeutics’ earnings. Vistagen Therapeutics reported earnings per share of ($0.24) in the same quarter last year, which suggests a negative year-over-year growth rate of 25%. The company is scheduled to announce its next earnings results on Monday, February 11th.

On average, analysts expect that Vistagen Therapeutics will report full year earnings of ($1.10) per share for the current fiscal year. For the next year, analysts forecast that the firm will report earnings of ($1.48) per share. Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for Vistagen Therapeutics.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Monday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.13).

Several analysts have recently commented on VTGN shares. Maxim Group set a $6.00 price objective on shares of Vistagen Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 6th. Oppenheimer set a $6.00 price objective on shares of Vistagen Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 24th. Zacks Investment Research raised shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Thursday, August 30th. Finally, ValuEngine raised shares of Vistagen Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $8.30.

Shares of VTGN stock traded down $0.04 during trading hours on Friday, hitting $2.00. 102,458 shares of the company were exchanged, compared to its average volume of 557,919. The company has a market cap of $64.29 million, a price-to-earnings ratio of -1.80 and a beta of -1.53. Vistagen Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $2.65.

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Article: How Investors Use a Balance Sheet

Get a free copy of the Zacks research report on Vistagen Therapeutics (VTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.